Sanofi (SNY) Projected to Post Quarterly Earnings on Thursday

Sanofi (NASDAQ:SNY - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, January 30th. Analysts expect Sanofi to post earnings of $0.70 per share and revenue of $10.57 billion for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to analysts' expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi's quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 earnings per share. On average, analysts expect Sanofi to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Sanofi Price Performance

NASDAQ SNY traded down $0.37 during trading hours on Tuesday, reaching $52.97. 2,123,042 shares of the company's stock were exchanged, compared to its average volume of 2,520,608. The firm has a fifty day moving average of $48.90 and a 200-day moving average of $52.22. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a one year low of $45.22 and a one year high of $58.97. The stock has a market cap of $134.43 billion, a PE ratio of 27.03, a price-to-earnings-growth ratio of 1.19 and a beta of 0.57.

Analysts Set New Price Targets

Separately, StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.